Pharmaceutical composition for bone repair and application thereof
Through the pharmaceutical compositions of quercetin, kaempferol and caffeic acid, combined with pharmaceutical excipients, the problem of insufficient repair ability of implanted materials in chronic osteomyelitis is solved, and long-acting bone repair and anti-inflammatory effects are achieved.
Patent Information
- Application Number
- CN202411035564.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-01
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
AI Technical Summary
The existing implanted materials used for the treatment of chronic osteomyelitis are insufficient in repair capacity when the defect range is large, and it is difficult to perform effective for a long time, and it is difficult to adjust the dosage of oral drugs.
Provided is a pharmaceutical composition comprising quercetin, kaempferol and caffeic acid, which is prepared into a variety of bone repair by inhibiting the NF-κB pathway, reducing ROS levels, promoting osteogenesis and inhibiting osteoclastic differentiation. Dosage form.
Significantly promote bone repair, improve the level of anti-inflammatory factors, inhibit bone rupture differentiation, enhance bone density and bone mineral content, and provide long-term bone repair effects.
Smart Images

Figure CN118903103A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a pharmaceutical composition for bone repair and use thereof. Background Art
[0002] During the bone repair stage, osteoblasts secrete collagen fibers around them, and complete the accumulation of bone with the deposition of calcium and the transformation of osteoblasts into osteocytes. During this period, pro-inflammatory factors will gradually decrease, and the corresponding anti-inflammatory factors will increase, which is conducive to the formation of a microenvironment conducive to osteogenesis locally. Osteogenesis and the reduction of inflammation can reflect the effect of drugs on bone repair.
[0003] Chronic osteomyelitis has a long recovery period, which requires drugs to be effective for a long time. Currently, active ingredients that promote osteoblastic function are encapsulated in implant materials for the treatment of chronic osteomyelitis. The loading and release performance of active ingredients play a vital role in osteoblastic ability. If the defect range is small, the size of the implant material will be limited. If the defect range is large, the existing implant materials will face problems such as insufficient later repair ability. For this problem, oral drugs are a good solution. Oral administration can adjust the dosage of the drug in time according to the progress of the disease.
[0004] There is no related report in the prior art on the use of the pharmaceutical composition of quercetin, kaempferol and caffeic acid claimed in the present invention in bone repair. Summary of the invention
[0005] Based on this, the present invention provides a pharmaceutical composition for bone repair, which comprises, by weight, 0.5 to 10 parts of quercetin as shown in formula I, 10 to 200 parts of kaempferol as shown in formula II, and 1 to 200 parts of caffeic acid as shown in formula III.
[0006]
[0007] Furthermore, the pharmaceutical composition comprises, by weight, 1 to 6 parts of quercetin as shown in formula I, 15 to 160 parts of kaempferol as shown in formula II, and 5 to 160 parts of caffeic acid as shown in formula III.
[0008] Furthermore, in parts by weight, the pharmaceutical composition comprises about 2.7 parts of quercetin as shown in formula I, about 158.5 parts of kaempferol as shown in formula II, and about 6 parts of caffeic acid as shown in formula III.
[0009] Furthermore, in parts by weight, the pharmaceutical composition comprises about 1 part of quercetin as shown in formula I, about 15.85 parts of kaempferol as shown in formula II, and about 150.35 parts of caffeic acid as shown in formula III.
[0010] Furthermore, in parts by weight, the pharmaceutical composition comprises about 1 part of quercetin as shown in formula I, about 47.55 parts of kaempferol as shown in formula II, and about 118.65 parts of caffeic acid as shown in formula III.
[0011] Furthermore, in parts by weight, the pharmaceutical composition comprises about 1 part of quercetin as shown in formula I, about 79.25 parts of kaempferol as shown in formula II, and about 86.95 parts of caffeic acid as shown in formula III.
[0012] Furthermore, in parts by weight, the pharmaceutical composition comprises about 1 part of quercetin as shown in formula I, about 158.5 parts of kaempferol as shown in formula II, and about 7.7 parts of caffeic acid as shown in formula III.
[0013] Furthermore, in parts by weight, the pharmaceutical composition comprises about 2.7 parts of quercetin as shown in formula I, about 15.85 parts of kaempferol as shown in formula II, and about 148.65 parts of caffeic acid as shown in formula III.
[0014] Furthermore, in parts by weight, the pharmaceutical composition comprises about 2.7 parts of quercetin as shown in formula I, about 79.25 parts of kaempferol as shown in formula II, and about 85.25 parts of caffeic acid as shown in formula III.
[0015] Furthermore, in parts by weight, the pharmaceutical composition comprises about 5 parts of quercetin as shown in formula I, about 15.85 parts of kaempferol as shown in formula II, and about 146.35 parts of caffeic acid as shown in formula III.
[0016] Furthermore, in parts by weight, the pharmaceutical composition comprises about 5 parts of quercetin as shown in formula I, about 79.25 parts of kaempferol as shown in formula II, and about 82.95 parts of caffeic acid as shown in formula III.
[0017] Further, the bone repair is bone repair in osteomyelitis such as chronic osteomyelitis.
[0018] Furthermore, the pharmaceutical composition further comprises one or more drugs, extracts and / or cells for bone repair.
[0019] Furthermore, the drug is selected from one or more of the following: cytokines, resveratrol and catechins.
[0020] Furthermore, the cytokine is bone morphogenetic protein (BMP-2).
[0021] Furthermore, the pharmaceutical composition is a traditional Chinese medicine composition.
[0022] Furthermore, the cells are mesenchymal stem cells.
[0023] According to another aspect of the present invention, there is provided a pharmaceutical preparation comprising the above pharmaceutical composition and one or more pharmaceutically acceptable excipients.
[0024] Furthermore, the auxiliary material is selected from one or more of the following: diluent, wetting agent, binder, disintegrant, inclusion agent, flavoring agent, sustained-release agent, retention agent, lubricant, dispersant, plasticizer, opacifier and antioxidant.
[0025] Furthermore, the pharmaceutical preparation is in the form of powder, tablet, pill, capsule, film, lozenge, granule, injection or oral solution.
[0026] According to another aspect of the present invention, there is provided a method for preparing the above-mentioned pharmaceutical composition, the method for preparing the pharmaceutical composition comprising the following steps:
[0027] (1) mixing the above-mentioned pharmaceutical composition and a pharmaceutically acceptable excipient, and heating until the pharmaceutically acceptable excipient is melted; wherein the weight ratio of the pharmaceutical composition to the pharmaceutically acceptable excipient is 1:0.1-100; and
[0028] (2) After mixing evenly, cooling, and pulverizing the mixture to obtain a powder of the pharmaceutical preparation.
[0029] According to another aspect of the present invention, there is provided a use of the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation in preparing a drug for bone repair.
[0030] Furthermore, the bone repair includes promoting osteogenesis, inhibiting osteoclast differentiation, blocking the NF-κB pathway to reduce inflammatory levels, reducing the generation of reactive oxygen species (ROS), reducing the level of pro-inflammatory factors and / or increasing the level of anti-inflammatory factors.
[0031] Furthermore, the pro-inflammatory factor is interleukin 1β (IL-1β), interleukin 6 (IL-6) and / or tumor necrosis factor α (TNF-α).
[0032] Furthermore, the anti-inflammatory factor is interleukin 4 (IL-4), interleukin 9 (IL-9), interleukin 10 (IL-10) and / or transforming growth factor β (TGF-β).
[0033] Beneficial effects of the present invention:
[0034] Alizarin red staining and ALP detection show that the pharmaceutical composition of quercetin, kaempferol and caffeic acid of the present invention can promote osteogenesis. TRAP staining and macrophage osteoclast differentiation-related gene detection prove that the pharmaceutical composition of quercetin, kaempferol and caffeic acid of the present invention can inhibit osteoclast differentiation. The NF-κB pathway is inhibited by the pharmaceutical composition of quercetin, kaempferol and caffeic acid of the present invention, and the ROS level is also reduced. In vivo and in vitro IL-6, IL-1β, TGF-β and IL-10 content detection proves that the pharmaceutical composition of quercetin, kaempferol and caffeic acid of the present invention can reduce pro-inflammatory factors and increase the level of anti-inflammatory factors. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without exceeding the scope of protection required by the present invention.
[0036] Figure 1 Schematic diagram of the ROS level detection results of different drug groups (quercetin-kaempferol-caffeic acid group). # , P<0.05, ## , P<0.01, ### , P < 0.001 vs combination 7; * , P<0.05, ** , P<0.01, *** , P<0.001vs control.
[0037] Figure 2 Schematic diagram of quantitative analysis results of Micro-CT data, including new bone volume / bone defect volume (a), bone density (b), CT value (c), and bone mineral content (d).
[0038] Figure 3 Schematic diagram of ROS fluorescence image (a) and quantitative analysis (b) results.
[0039] Figure 4 Schematic diagram of the in vitro toxicity (CCK-8 method) results of quercetin-kaempferol-caffeic acid at different concentrations.
[0040] Figure 5 Schematic diagram of the results of liver and kidney hematoxylin-eosin staining (5X, 20X).
[0041] Figure 6 Schematic diagram of Alizarin red staining (a) and semi-quantitative analysis (b) results.
[0042] Figure 7Schematic diagram of alkaline phosphatase content (a) and alkaline phosphatase / total protein ratio (b).
[0043] Figure 8 Schematic diagram of the results of hematoxylin-eosin staining (5X, 20X).
[0044] Fig. 9 Schematic diagram of Masson staining results.
[0045] Fig.10 Schematic diagram of the results of tartrate-resistant acid phosphatase staining (a), osteoclast number (b), and osteoclast area quantification (c).
[0046] Fig.11 Figure 2 is a heat map of osteoclast-related factor expression levels (a) and a schematic diagram of quantitative analysis results (b).
[0047] Fig.12 Schematic diagram of the nuclear fluorescence image (a) and quantitative analysis (b) results of P65 in the NF-κB pathway.
[0048] Fig.13 Schematic diagram of the quantitative analysis results of the expression levels of cellular pro-inflammatory factors (IL-1β (a), IL-6 (b)) and anti-inflammatory factors (TGF-β (c), IL-10 (d)).
[0049] Fig.14 This is a schematic diagram of the time scale quantitative analysis results of the expression levels of serum pro-inflammatory factors (IL-1β, IL-6) and anti-inflammatory factors (TGF-β, IL-10). DETAILED DESCRIPTION
[0050] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0051] Unless otherwise indicated, all technical and scientific terms and abbreviations used herein have the meanings commonly understood by those of ordinary skill in the field of the invention or the field in which the terms are used. Although any methods, conditions, substances or materials similar to or equivalent to those disclosed herein may be used in the practice of the present invention, preferred methods, conditions, substances or materials are described herein.
[0052] The present invention is intended to encompass all alternatives, variations and equivalents that may be included in the present invention as defined by the claims. Those skilled in the art will recognize many methods and materials similar or equivalent to those described herein that can be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described.
[0053] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0054] In the present invention, the term "comprising" is synonymous with "including". As used herein, the terms "comprising", "including", "having", "containing" or any other variation thereof are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus comprising the listed elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
[0055] As described in the background technology section, the current method of treating chronic osteomyelitis by encapsulating the active ingredient that promotes osteogenic effect in an implant material faces the problems of small defect range, limited implant material size, large defect range, and insufficient later repair ability of existing implant materials. In order to solve the above problems, the present invention provides a pharmaceutical composition for bone repair, which comprises 0.5 to 10 parts of quercetin as shown in formula I, 10 to 200 parts of kaempferol as shown in formula II, and 1 to 200 parts of caffeic acid as shown in formula III, in parts by weight.
[0056]
[0057] The pharmaceutical composition of quercetin, kaempferol and caffeic acid (i.e. Qu-Ka-Ca) of the present invention has the effect of inhibiting osteoclasts and promoting osteogenesis, can inhibit the NF-κB pathway and the generation of ROS, and has the ability to promote the expression of anti-inflammatory factors and the expression of pro-inflammatory factors.
[0058] In the present invention, when weight parts, weight ratios, time, pressure, ratios, equivalents, concentrations, or other values or parameters are expressed as ranges, preferred ranges, or a series of upper preferred values and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when the range "0.5-10" is disclosed, the described range should be interpreted as including the range "1-10", "2-10", "3-10", "4-10", "5-10", "6-10", "7-10", "8-10", "9-10", "1-9", "2-9", "3-9", "4-9", "5-9", "6-9", "7-9", "8-9", "2-6", "3-7", "2-7", "3-5", "4-6", "5-7", "2-5", "3-6", "4-7", "2-6", "3-7", "2-7", etc. When a numerical range is described herein, unless otherwise indicated, that range is intended to include the endpoints and all integers and fractions within that range.
[0059] In a preferred embodiment, the pharmaceutical composition comprises, by weight, 1 to 6 parts of quercetin as shown in formula I, 15 to 160 parts of kaempferol as shown in formula II, and 5 to 160 parts of caffeic acid as shown in formula III.
[0060] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 1 part of quercetin as shown in formula I, about 15.85 parts of kaempferol as shown in formula II, and about 150.35 parts of caffeic acid as shown in formula III.
[0061] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 1 part of quercetin as shown in formula I, about 47.55 parts of kaempferol as shown in formula II, and about 118.65 parts of caffeic acid as shown in formula III.
[0062] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 1 part of quercetin as shown in formula I, about 79.25 parts of kaempferol as shown in formula II, and about 86.95 parts of caffeic acid as shown in formula III.
[0063] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 1 part of quercetin as shown in formula I, about 158.5 parts of kaempferol as shown in formula II, and about 7.7 parts of caffeic acid as shown in formula III.
[0064] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 2.7 parts of quercetin as shown in formula I, about 15.85 parts of kaempferol as shown in formula II, and about 148.65 parts of caffeic acid as shown in formula III.
[0065] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 2.7 parts of quercetin as shown in formula I, about 79.25 parts of kaempferol as shown in formula II, and about 85.25 parts of caffeic acid as shown in formula III.
[0066] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 2.7 parts of quercetin as shown in formula I, about 158.5 parts of kaempferol as shown in formula II, and about 6 parts of caffeic acid as shown in formula III.
[0067] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 5 parts of quercetin as shown in formula I, about 15.85 parts of kaempferol as shown in formula II, and about 146.35 parts of caffeic acid as shown in formula III.
[0068] In a preferred embodiment, the pharmaceutical composition comprises, by weight, about 5 parts of quercetin as shown in formula I, about 79.25 parts of kaempferol as shown in formula II, and about 82.95 parts of caffeic acid as shown in formula III.
[0069] In the present invention, "about" refers to a value within the range of ±5% of a specific value. For example, "about 1" includes ±5% of 1, or from 0.95 to 1.05; "about 15.85" includes ±5% of 15.85, or from 15.0575 to 16.6425; "about 150.35" includes ±5% of 150.35, or from 142.8325 to 157.8675; "about 47.55" includes ±5% of 47.55, or from 45.1725 to 49.9275; "about 118. "65" includes ±5% of 118.65, or from 112.7175 to 124.5825; "about 79.25" includes ±5% of 79.25, or from 75.2875 to 83.2125; "about 86.95" includes ±5% of 86.95, or from 82.6025 to 91.2975; "about 158.5" includes ±5% of 158.5, or from 150.575 to 166.425; " "About 7.7" includes ±5% of 7.7, or from 7.315 to 8.085; "about 2.7" includes ±5% of 2.7, or from 2.565 to 2.835; "about 148.65" includes ±5% of 148.65, or from 141.2175 to 156.0825; "about 85.25" includes ±5% of 85.25, or from 80.9875 to 89.5125; "about 6" includes ±5% of 6, Or from 5.7 to 6.3; "about 5" includes ±5% of 5, or from 4.75 to 5.25; "about 15.85" includes ±5% of 15.85, or from 15.0575 to 16.6425; "about 146.35" includes ±5% of 146.35, or from 139.0325 to 153.6675; "about 82.95" includes ±5% of 82.95, or from 78.8025 to 87.0975.
[0070] In a preferred embodiment, the bone repair is bone repair in osteomyelitis, such as chronic osteomyelitis.
[0071] In a preferred embodiment, the pharmaceutical composition further comprises one or more drugs, extracts and / or cells for bone repair.
[0072] In a preferred embodiment, the drug is selected from one or more of the following: cytokines, resveratrol and catechins.
[0073] In a preferred embodiment, the cytokine is bone morphogenetic protein (BMP-2).
[0074] In a preferred embodiment, the pharmaceutical composition is a traditional Chinese medicine composition.
[0075] In a preferred embodiment, the cells are mesenchymal stem cells.
[0076] According to another aspect of the present invention, there is provided a pharmaceutical preparation comprising the above pharmaceutical composition and one or more pharmaceutically acceptable excipients.
[0077] In a preferred embodiment, the pharmaceutical preparation of the present invention contains at least one pharmaceutically acceptable excipient in an amount of 0.00001 to 50 wt.%, or 0.0001 to 10 wt.%, or 0.0001 to 5 wt.%, or 0.005 to 1 wt.%, or 0.1 to 20 wt.%, or 0.5 to 15 wt.%, or 1 to 5 wt.%, based on the weight of the pharmaceutical preparation.
[0078] In the present invention, the term "pharmaceutically acceptable" refers to a substance, such as a carrier or diluent, that does not abrogate the biological activity or properties of the compound and is relatively non-toxic, i.e., a substance that does not cause undesirable biological effects or interact in a deleterious manner with any of its components when administered to an individual.
[0079] In the present invention, the term "pharmaceutically acceptable excipient" refers to carriers and / or excipients that are pharmacologically and / or physiologically compatible with subjects and active ingredients (i.e., capable of inducing the desired therapeutic effect without causing any undesirable local or systemic effects), which are well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995).
[0080] In a preferred embodiment, the auxiliary material is selected from one or more of the following: diluent, wetting agent, binder, disintegrant, inclusion agent, flavoring agent, sustained-release agent, retention agent, lubricant, dispersant, plasticizer, opacifier and antioxidant.
[0081] Those skilled in the art will know how to select specific chemical substances within the scope of the above-mentioned auxiliary material category.For example, the diluent can be selected from one or more of the following: icing sugar, starch, compressible starch, lactose, dextrin, mannitol, sorbitol, microcrystalline cellulose, calcium sulfate and calcium carbonate.The wetting agent can be selected from one or more of the following: polyoxymethylene stearate, poloxamer, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, polysorbate such as polysorbate 80, cetyl alcohol, glycerol fatty acid ester (such as triacetin, glyceryl monostearate and the like), polyoxyethylene fatty acid ester, polyethylene glycol fatty acid ester, sodium lauryl sulfate, sorbitol fatty acid ester, sucrose fatty acid ester, polyoxyethylene ether, benzalkonium chloride, polyoxyethylene castor oil and docusate sodium.The adhesive can be selected from one or more of the following: polyvinyl pyrrolidone, hydroxypropyl cellulose, polyethylene glycol and methylcellulose. The disintegrant may be selected from one or more of the following: carboxymethylcellulose, carboxymethylcellulose calcium salt and sodium carboxymethylcellulose. The flavoring agent may be selected from one or more of the following: sorbitol, glucose, mannose, sucrose and lactose. The dispersant may be selected from one or more of the following: cross-linked sodium carboxymethylcellulose, sodium starch glycolate and pre-gelatinized corn starch. The plasticizer may be dibutyl sebacate and / or various citrates. The sustained-release agent may be selected from one or more of the following: sodium carboxymethylcellulose, low-substituted hydroxypropylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, hydroxyethylcellulose, gum arabic, gelatin and shellac. The antioxidant may be selected from one or more of the following: sodium bisulfite, sodium pyrosulfite, sodium sulfite and sodium thiosulfate. The lubricant may be selected from one or more of the following: calcium stearate, talc, magnesium stearate, stearic acid and colloidal silicon dioxide.
[0082] These excipients are preferably pharmaceutically inert, or may have a synergistic or additive effect to enhance the therapeutic activity of the pharmaceutical composition, and the above-mentioned excipients are only listed. The excipients actually used in the present invention are not limited to the above-mentioned excipients and can be adjusted according to actual conditions to achieve the effects of the present invention.
[0083] In a preferred embodiment, the pharmaceutical preparation is a powder, tablet, pill, capsule, film, lozenge, granule, injection or oral solution.
[0084] According to another aspect of the present invention, there is provided a method for preparing the above-mentioned pharmaceutical composition, the method for preparing the pharmaceutical composition comprising the following steps:
[0085] (1) mixing the above-mentioned pharmaceutical composition and a pharmaceutically acceptable excipient, and heating until the pharmaceutically acceptable excipient is melted; wherein the weight ratio of the pharmaceutical composition to the pharmaceutically acceptable excipient is 1:0.1-100; and
[0086] (2) After mixing evenly, cooling, and pulverizing the mixture to obtain a powder of the pharmaceutical preparation.
[0087] According to another aspect of the present invention, there is provided a use of the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation in preparing a drug for bone repair.
[0088] In a preferred embodiment, the bone repair includes promoting osteogenesis, inhibiting osteoclast differentiation, blocking the NF-κB pathway to reduce inflammatory levels, reducing the generation of reactive oxygen species (ROS), reducing the level of pro-inflammatory factors and / or increasing the level of anti-inflammatory factors.
[0089] In a preferred embodiment, the pro-inflammatory factor is interleukin 1β (IL-1β), interleukin 6 (IL-6) and / or tumor necrosis factor α (TNF-α).
[0090] In a preferred embodiment, the anti-inflammatory factor is interleukin 4 (IL-4), interleukin 9 (IL-9), interleukin 10 (IL-10) and / or transforming growth factor β (TGF-β).
[0091] According to another aspect of the present invention, there is provided the above composition or the above pharmaceutical preparation for use in bone repair in a subject.
[0092] According to another aspect of the present invention, a method for bone repair in a subject is provided, comprising administering an effective amount of the above composition or the above pharmaceutical preparation to the subject.
[0093] In the present invention, the term "subject" is a mammal. The mammal may be a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse or a cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects representing bone injury models. Preferably, the subject is a human.
[0094] The "effective amount" of the pharmaceutical composition or preparation used in the present invention can obtain the desired treatment and / or prevention effect. The amount effective for this purpose will depend on, for example, the pharmaceutical composition, the mode of administration, the stage and severity of the disease to be treated, the individual's body weight and overall health, and the judgment of the prescribing physician. The dosage can be given once a week, or once every two days or every day, or even several times a day. The dosage unit can be given in a short period of time (e.g., weeks to months) or longer time periods (months to years).
[0095] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions or conditions recommended by the manufacturer.
[0096] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0097] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in this patent specification can be used in combination with any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.
[0098] Example
[0099] 1 Materials and methods
[0100] 1.1 Experimental reagents and instruments
[0101] Table 1 Main raw materials and reagents
[0102]
[0103]
[0104] Table 2 Experimental instruments and equipment
[0105]
[0106]
[0107] 1.2 In vivo effectiveness verification of drug composition
[0108] 1.2.1 Establishment of mouse chronic osteomyelitis model
[0109] All animal experiment protocols of the present invention have been approved by the Animal Experiment Ethics Committee. During the experiment, the animals were kept in a constant temperature, constant pressure, and constant humidity environment, and had free access to food and water.
[0110] In order to verify whether the pharmaceutical composition of the present invention can still help repair bone defects in chronic osteomyelitis in animals, a mouse femoral chronic osteomyelitis model was constructed in the animal experiment of the present invention. Before the experiment, C57 mice (male, weight 15-25g, 6 weeks old, Shanghai Jiesijie Experimental Animal Co., Ltd.) were fasted for 6 hours, and water was freely available during the period. 50 6-week-old C57 male mice were taken.
[0111] (1) Mice were intraperitoneally injected with 0.15 mL of 1% pentobarbital;
[0112] (2) After anesthetization, shave the hair on the surface of the left femur of the anesthetized mouse while the mouse is in a naturally flexed knee position. Disinfect the epidermis with a 75% alcohol cotton ball;
[0113] (3) Use forceps to pinch the skin in the middle of the femur perpendicular to the long axis of the femur, use flat scissors to make a small cut, then cut the skin about 1 cm along the long axis of the femur, use the tip of surgical scissors to carefully cut the fascia and superficial muscles, and then use blunt forceps to bluntly separate the deep muscles until the femoral shaft is exposed;
[0114] (4) Use forceps to keep the femur exposed, and then use a 0.6 mm small animal bone drill to make a unilateral hole in the femoral shaft;
[0115] (5) Use a Hamilton syringe to draw 1 μL (CFU = 1×10 8 ) Staphylococcus aureus liquid is injected into the bone marrow cavity from the drill hole, and the syringe is withdrawn after a short stay to allow the liquid to infiltrate the bone marrow cavity;
[0116] (6) Suture the muscles and skin of the mouse with absorbable sutures, and finally disinfect the body surface with iodine cotton balls;
[0117] (7) Similarly, all mice were modeled according to the above steps, except that the sterile group was injected with sterile PBS into the bone marrow cavity.
[0118] 1.2.2 Group gavage treatment
[0119] The control group, quercetin group, kaempferol group, caffeic acid group, quercetin-kaempferol group, quercetin-caffeic acid group, kaempferol-caffeic acid group, and quercetin-kaempferol-caffeic acid group were divided into 5 groups. According to the daily gavage volume of 0.5 mL for 6-8 week old mice, the gavage concentration of quercetin was 10.8 μg / mL, the gavage concentration of kaempferol was 634 μg / mL, and the gavage concentration of caffeic acid was 24 μg / mL. 0.5% sodium carboxymethyl cellulose (CMC-Na) was used as a cosolvent when preparing the solution. The preparation of each group of drugs was based on: gavage days × gavage concentration × number of mice in each group, and the drugs were stored at -20°C after preparation. The therapeutic effect of each group was evaluated by tissue staining and other methods.
[0120] 1.3 ROS level detection
[0121] Macrophages RAW264.7 (commercially available) were inoculated in confocal dishes. Two dishes (control group and Qu-Ka-Ca group) were set up, and 2×10 4cells. On the second day, aspirate the culture medium in the dish, add serum-free culture medium (1% double antibody + 0.2% BSA + 98.8% α-MEM) and starve for 3 hours. Add 250μl of 2ng / mL TNF-α + (PBS, Qu-Ka-Ca) + complete culture medium and culture for 16 hours. Aspirate the culture medium in the dish, add 1mL of diluted ROS probe (DCFH-DA) to each dish, and culture in a 37°C incubator in the dark for 20 minutes. Wash the confocal dish with PBS three times, and finally add 100μL of PBS to the dish to detect fluorescence at 488nm under a confocal microscope. The results are as follows: Figure 1 shown.
[0122] Table 3 Experimental groups (uniform design)
[0123] Concentration gradient Quercetin μg Kaempferol μg Caffeic acid μg Total dose μg 1 1.00 15.85 150.35 167.20 2 1.00 47.55 118.65 167.20 3 1.00 79.25 86.95 167.20 4 1.00 158.50 7.70 167.20 5 2.70 15.85 148.65 167.20 6 2.70 79.25 85.25 167.20 7 2.70 158.50 6.00 167.20 8 5.00 15.85 146.35 167.20 9 5.00 79.25 82.95 167.20
[0124] The above drug dosages are calculated based on a sample volume of 250 μl.
[0125] according to Figure 1 The experimental results of the present invention are as follows. The following subsequent experiments of the present invention are continued using the ratio 7 in Table 3.
[0126] 1.4 Extraction of mouse mesenchymal stem cells and monocytes
[0127] 1.4.1 Extraction of mouse bone marrow mesenchymal stem cells
[0128] (1) Prepare solution A in a clean bench: 20 mL of α-MEM medium containing 10% FBS and 1% double antibody, solution B (staying buffer): 2% FBS + HANKS balanced salt buffer solution (HBSS) (without calcium and magnesium) 2 mL, solution C (digestion solution) × 3: 100 μL collagenase type 1 + 100 μL Nettral protease + 20 μL DNAse + 800 μL HBSS (with calcium and magnesium), solution D (digestion stop solution): 40 μL EDTA + 10 mL HBSS (without calcium and magnesium);
[0129] (2) After killing the mice by cervical dislocation, the mice were soaked in 75% alcohol for 5 min, and the femur and tibia of the mice were carefully separated. The soft tissue attached to the femur and tibia was peeled off with dust-free paper;
[0130] (3) Use sterile straight scissors to cut off both ends of the femur and tibia. Use a 1 mL syringe to draw an appropriate amount of liquid A and insert it from one end of the bone shaft to quickly flush out the bone marrow. Then insert it from the other end to flush the bone marrow. Repeat the flushing until the bone shaft turns white.
[0131] (4) the obtained cell-containing liquid was centrifuged at 300 g for 5 min at room temperature;
[0132] (5) Place the remaining bone in a mortar and add 1-2 mL of liquid B for grinding;
[0133] (6) Transfer the ground bones and liquid to a centrifuge tube and centrifuge at 300 g for 5 min at room temperature;
[0134] (7) Pour off the supernatant, add 1 mL of solution C to both tubes and place in a 37°C water bath for 15 min, then vortex three times (use a trimmed pipette tip during this process);
[0135] (8) Add solution D to both tubes for 1 min to inactivate the enzyme. This process should be performed on ice.
[0136] (9) Centrifuge the two tubes at 300 g for 10 min at room temperature;
[0137] (10) Remove the supernatant and add 1 mL of solution B, gently pipetting to resuspend;
[0138] (11) The digested cells were filtered through a 40 μm filter into a flow tube and centrifuged at 300 g for 5 min at room temperature;
[0139] (12) Discard the supernatant, re-add Solution A, pipette gently to resuspend, and inoculate into a culture dish;
[0140] (13) The culture medium was replaced every two days, and the cells were subcultured on the 7th day, which was the P1 generation.
[0141] 1.4.2 Mononuclear cell extraction from mouse bone marrow
[0142] (1) Prepare solution A in a clean bench: 10 mL of α-MEM medium containing 20% FBS and 1% double antibody, solution B: 15 mL of PBS solution containing 1% FBS, and solution C: 50 mL of α-MEM medium containing 10% FBS, 1% double antibody, and 20 ng / mL macrophage colony stimulating factor (M-CSF);
[0143] (2) After killing the mice by cervical dislocation, the mice were soaked in 75% alcohol for 5 min. The femur and tibia of the mice were carefully separated, and the soft tissue attached to the femur and tibia was peeled off with dust-free paper, and then placed in solution B for infiltration;
[0144] (3) Use sterile straight scissors to cut off both ends of the femur and tibia. Use a 1 mL syringe to draw an appropriate amount of liquid A and insert it from one end of the femur or tibia to quickly flush out the bone marrow contents. Then insert it from the other end and repeat the above steps until the femur and tibia are flushed to white.
[0145] (4) Place the flushed bone marrow contents in a 15 mL centrifuge tube and repeatedly pipette with a 1 mL sterile pipette tip to disperse them;
[0146] (5) Centrifuge the completely washed cell suspension at 300 g for 5 min at room temperature and remove the supernatant;
[0147] (6) Add 5 mL of red blood cell lysis buffer to the centrifuged cells, lyse at room temperature for 3 min, then add 5 mL of solution B for neutralization, and centrifuge at 300 g for 5 min at room temperature;
[0148] (7) Then remove the supernatant. Add 10 mL of solution C, pipette to suspend, then pour the cell suspension into a 10 cm cell culture dish and culture in a 37°C, 5% CO2 incubator;
[0149] (8) The next day, pipette the culture suspension into a centrifuge tube and centrifuge at 300 g for 5 min at room temperature. Remove the supernatant and add Solution C to resuspend the culture.
[0150] 1.5 Mesenchymal stem cell proliferation and toxicity experiments
[0151] Mesenchymal stem cell proliferation experiment:
[0152] Mesenchymal stem cells (BMSC) were cultured to p3 and seeded in three 96-well plates, which were tested at 1, 4, and 7 days. Seven groups were set up in each plate (containing 100 ng / mL quercetin, 100 ng / mL kaempferol, 2.5 μg / mL caffeic acid, and 0.5% CMC-Na solution as standard concentrations, and 0.1, 0.3, 3, and 9 times the standard concentration as concentration gradients, and also including a 0.5% CMC-Na group and a control group).
[0153] (1) Each group has three wells, and each well is inoculated with 8×10 3 cells, and 50 μL of different concentrations of Qu-Ka-Ca or CMC-Na were added to each well;
[0154] (2) Each time you test, first remove the culture medium from the wells. Wash the wells with sterile PBS;
[0155] (3) Add 10 μL CCK-8 and 90 μL complete medium to each well (set the wells without cells as blank wells and also add 10 μL CCK-8 and 90 μL complete medium to each well);
[0156] (4) Incubate in a 37°C incubator in the dark for 120 min. Measure the absorbance at 490 nm using an ELISA reader.
[0157] Hepatotoxicity test:
[0158] According to the above tissue sectioning method and HE staining method, the liver and kidney of the mice in the control group and the drug group were stained. The morphology of the hepatic sinusoids and renal tubules in the sections was observed under an inverted microscope.
[0159] 1.6 Promoting osteogenic differentiation
[0160] 1.6.1 Alizarin red staining
[0161] BMSCs of generation p3 were seeded in 24-well plates and three groups (control group, Qu-Ka-Ca group, and CMC-Na group) were set up. 2×10 4 cells. Prepared into bone induction medium: 500 μL double antibody, 1 mL fetal bovine serum, 1.962×10 - 3 mg dexamethasone, 1.04 mg β-glycerophosphate sodium, 0.44 mg ascorbic acid, 49 mL α-MEM. On the second day, remove the culture medium in the wells and add 1 mL of prepared osteogenic induction medium and 250 μL PBS, 0.5% CMC-Na, Qu-Ka-Ca to each well. Change the liquid every three days and test on the 21st day. Remove the culture medium in the well plate and wash once with PBS. Add 500 μL of prepared fixative to each well and fix at room temperature for 20 minutes. Wash 3 times with PBS. Add 200 μL Alizarin Red S staining solution and stain at room temperature for 30 minutes. Wash with distilled water and observe under an inverted microscope.
[0162] 1.6.2 Alkaline phosphatase content detection
[0163] P3 generation BMSCs were seeded in 24-well plates and three groups (control group, CMC-Na group, Qu-Ka-Ca group) were set up. 2×10 4 Prepare 50 mL of osteogenic induction medium: 500 μL of double antibody, 1 mL of fetal bovine serum, 1.962×10 -3 mg dexamethasone, 1.04 mg β-glycerophosphate sodium, 0.44 mg ascorbic acid, 48.5 mL α-MEM. On the second day, remove the culture medium in the wells, add 1 mL of prepared osteogenic induction medium and 250 μL PBS, 0.5% CMC-Na, Qu-Ka-Ca to each well. Change the medium every three days, and perform ALP detection on the ninth day. The specific steps are as follows:
[0164] (1) Remove the culture medium from the wells, wash with PBS three times, add 200 μL of inhibitor-free cell lysis buffer to each well, and lyse on ice for five minutes;
[0165] (2) Pipette all the liquid in the well into a centrifuge tube and centrifuge at 12000 rpm and 4°C for 5 min;
[0166] (3) Take 100 μL of the supernatant and add 200 μL of PBS for dilution;
[0167] (4) Add 2, 4, 8, 16, 24, 32 and 40 μL of the prepared standard and the diluted sample to a 96-well plate, respectively. Set up three replicate wells for each sample group, add 50 μL of sample to each well, and set up three blank wells;
[0168] (5) Add 98, 96, 92, 84, 76, 68, and 60 μL of detection buffer to the standard wells, respectively, so that the total liquid volume in each well is 100 μL, and add 50 μL of detection buffer to the blank well;
[0169] (6) Add 50 μL of the prepared chromogenic substrate solution to the blank well and the sample well. Mix well and incubate in a 37°C incubator for 20 min. Add 100 μL of the reaction stop solution to each well.
[0170] (7) Detecting the absorbance of each well at 405 nm in an ELISA reader;
[0171] (8) After sample dilution, take 20 μL for total protein (BCA) detection. Set up three replicate wells for each sample group and add the samples to a 96-well plate;
[0172] (9) Take 0.8 mL of protein standard preparation solution and add it to a tube of protein standard (20 mg bovine serum albumin (BSA)) and prepare a 25 mg / mL protein standard solution after it is fully dissolved;
[0173] (10) Take 1 μL of 25 mg / mL protein standard solution and add it to 49 μL of protein standard diluent to achieve a final concentration of 0.5 mg / mL;
[0174] (11) 0, 1, 2, 4, 8, 12, 16, and 20 μL of protein standard solution (ρ = 0.5 mg / mL) were added to a 96-well plate, and then the 8 standard wells were filled to 20 μL with protein standard diluent;
[0175] (12) Prepare 5 mL of BCA working solution: 4900 μL of BCA reagent A plus 100 μL of BCA reagent B. Add 200 μL of BCA working solution to both the standard well and the sample well;
[0176] (13) Incubate at 37°C for 30 min. Measure the absorbance of each well at 562 nm using an ELISA reader.
[0177] 1.7 Inhibit osteoclast differentiation ability
[0178] Tartrate-resistant acid phosphatase (TRAP) staining was used to measure the total number of macrophages. Macrophages were inoculated in 24-well plates and three groups were set up: control group (sterile PBS), CMC-Na group (0.5% CMC-Na), Qu-Ka-Ca group (quercetin-kaempferol-caffeic acid), and 2×10 5 cells, the culture medium components are: 20ng / mL M-CSF, 200ng / mL nuclear factor κB receptor activator ligand (RANKL), 1% double antibody (penicillin, streptomycin), 10% fetal bovine serum, 89% α-MEM. Each group was added with 250μL PBS, 0.5% CMC-Na, Qu-Ka-Ca. The medium was changed every three days, and the culture medium was removed on the ninth day. Wash three times with PBS, add 500μL 4% paraformaldehyde to each well to fix the cells for 20min. Wash three times with PBS, add 500μL of the prepared TRAP staining solution, and culture in a 37℃ incubator for 1h. Wash three times with PBS, and observe osteoclasts under an inverted microscope.
[0179] 1.8 Characterization of anti-inflammatory ability
[0180] 1.8.1 NF-κB pathway detection
[0181] Macrophages were inoculated in confocal dishes and three groups (control group, CMC-Na group, Qu-Ka-Ca group) were set up, with 5×10 macrophages in each dish. 4cells. Add 1mL of culture medium, 250μL of PBS, CMC-Na, and Qu-Ka-Ca to each dish, and culture in a 37℃ incubator for 12h for pretreatment. The next day, remove the culture medium in the wells, add serum-free culture medium (1% double antibody + 0.2% BSA + 98.8% α-MEM) and starve for 4h. Remove the culture medium in the wells, wash the confocal dish 3 times with PBS, add 1mL of complete culture medium containing 2ng / mL TNF-α to each well, and add 250μL of PBS, CMC-Na, and Qu-Ka-Ca to co-culture for 1h. Remove the culture medium and wash once with PBS. Add 1mL of fixative and fix for 10min. Remove the fixative and wash 3 times with washing solution, and stay for 3-5min after adding washing solution each time. Add 1mL of immunostaining blocking solution and block at room temperature for 1 hour. Remove the immunostaining blocking solution, add 500μL of NF-κBp65 mouse monoclonal antibody, and incubate overnight in a 4℃ refrigerator. Aspirate the NF-κB p65 mouse monoclonal antibody in the confocal dish. Wash 3 times with washing solution, and keep it for 10 minutes after each addition of washing solution. Add 1mL anti-mouse Cy3 to each confocal dish and incubate at room temperature for 1h. Aspirate the anti-mouse Cy3, wash 2 times with washing solution, and keep it for 10 minutes after each addition of washing solution. Add 1mL of cell nucleus staining solution (DAPI) to the confocal dish and stain for about 5 minutes at room temperature. Aspirate the cell nucleus staining solution, wash 3 times with washing solution, and keep it for 5 minutes after each addition of washing solution. Add 200μL of anti-fluorescence quenching sealing solution, cover the slide and observe under a confocal microscope. NF-κB staining is red fluorescence, and DAPI staining of cell nuclei is blue fluorescence.
[0182] 1.8.2 Detection of inflammatory factor levels in vivo
[0183] Fix the mouse, dip alcohol in absorbent cotton, and disinfect the scissors and the mouse tail. Cut off 2mm of the tail with flat scissors, and collect 0.5mL of blood in a centrifuge tube. After the blood sample is left to stand for 6 hours, take the supernatant and centrifuge it at 1200r / min and 4℃ for 10 minutes. Take the supernatant and detect the corresponding inflammatory-related factors according to the instructions of the Elisa test kit.
[0184] 1.8.3 In vitro inflammatory factor level detection
[0185] Macrophages were inoculated in 24-well plates, with 3 wells (control group, CMC-Na group, Qu-Ka-Ca group) set up, and 5×10 4cells. On the second day, the culture medium in the wells was removed, and serum-free culture medium (1% double antibody + 0.2% BSA + 98.8% α-MEM) was added to starve for 4 hours. The culture medium in the wells was removed, and 1 mL of complete culture medium containing 2 ng / mL TNF-α was added to each well, and 250 μL (PBS, CMC-Na, Qu-Ka-Ca) was added to stimulate for 18 hours. The supernatant was collected and tested according to the method of the Elisa detection kit.
[0186] 1.9qPCR
[0187] Macrophages were seeded in 6-well plates (8×10 5 Cells were collected and three groups (control group, CMC-Na group, Qu-Ka-Ca group) were set up. The complete culture medium containing 200ng / mL RANKL and 40ng / mL M-CSF was replaced every two days. On the third day, mRNA was extracted and tested. The specific steps were as follows:
[0188] (1) Wash the plate three times with cold PBS;
[0189] (2) Add 1 mL of TRIzol lysis buffer to the well plate using an enzyme-free pipette tip in a clean bench and lyse on ice for 10 min.
[0190] (3) After blowing with a pipette tip, the tube was collected into an enzyme-free centrifuge tube, 200 μL of chloroform was added, and the tube was shaken for 15 seconds and then placed on ice for 10 minutes;
[0191] (4) Centrifuge at 12000 rpm and 4°C for 15 min;
[0192] (5) Take 400 μL of supernatant and add it to a new enzyme-free centrifuge tube, add 500 μL of isopropanol, mix thoroughly and let stand on ice for 10 min;
[0193] (6) Centrifuge at 12000 rpm and 4°C for 15 min;
[0194] (7) Pour off the supernatant, add 1 mL of 75% ethanol solution (750 μL of anhydrous ethanol, 250 μL of DEPC water (nuclease-free water without RNase)), invert 10 times, and let stand on ice for 10 min;
[0195] (8) Centrifuge at 10,000 rpm and 4°C for 10 min;
[0196] (9) Pour off the supernatant, tap gently on filter paper until there is no obvious moisture, and then invert to dry for 3 minutes;
[0197] (10) Add 8 μL of DEPC water and take 1 μL to detect its concentration;
[0198] (11) If the concentration is higher than 800 ng / mL, dilute to this value with DEPC water;
[0199] (12) Take 6.5 μL of the diluted mRNA solution into a new enzyme-free tube, and then add 3.5 μL of the prepared reverse transcription reagent;
[0200] (13) After reverse transcription into cDNA, dilute 10 times, and after dilution, prepare a 20 μL fluorescence quantitative system according to 10 μL TB Green, 0.4 μL upstream primer, 0.4 μL downstream primer, 1 μL cDNA, and 8.2 μL DEPC water;
[0201] (14) Collecting fluorescence quantitative data in a PCR amplification instrument.
[0202] 1.10 Statistical methods
[0203] The experimental data are expressed as mean ± standard deviation of at least three independent experiments. The t-test was used to compare the experimental groups with the control group. P>0.05 indicates no significant difference; p<0.05 indicates a significant difference, which is statistically significant; p<0.01, p<0.001 and p<0.0001 all indicate extremely significant differences, and the smaller the p value, the more significant the difference.
[0204] 2 Results and discussion
[0205] 2.1 Effectiveness of drug composition
[0206] like Figure 2 As shown, the new bone volume / bone defect volume (BV / TV) after 14 days of gavage with quercetin solution was 59.2%, the BV / TV after 14 days of gavage with kaempferol solution was 59.3%, the BV / TV after 14 days of gavage with quercetin+kaempferol solution was 50.8%, the BV / TV after 14 days of gavage with quercetin+caffeic acid solution was 53.3%, the BV / TV after 14 days of gavage with caffeic acid+kaempferol solution was 52.1%, and the BV / TV after 14 days of gavage with quercetin+kaempferol+caffeic acid solution was 72.08%. Other indicators such as bone density (BMD), CT value (CTValue) and bone mineral content (BMC) all show that the combination of quercetin, kaempferol and caffeic acid has the best effect.
[0207] 2.2 Detection of reactive oxygen species (ROS) levels
[0208] Reactive oxygen species (ROS) are mainly formed by the electrons generated by mitochondrial respiratory metabolism binding to oxygen molecules. Reactive oxygen species are generated in normal cell metabolism, and reactive oxygen species are the main mediators for phagocytic cells to exert phagocytic and bactericidal effects. However, under certain stimuli, such as the antigen on the surface of Staphylococcus aureus binding to the target protein on the surface of phagocytic cells, cells can be induced to produce a large amount of ROS, and the production of a large amount of ROS can damage normal cells, which is also not conducive to tissue repair under pathological conditions. Therefore, the production of ROS is very important for body immunity and tissue repair. In chronic osteomyelitis, bacteria avoid being killed by immune cells in the form of biofilms, and re-proliferate under certain conditions, inducing phagocytic cells to produce a large amount of ROS, aggravating bone destruction. Therefore, in chronic osteomyelitis, the production of ROS should be reduced to reduce bone destruction and promote bone repair. Macrophages are one of the main cells that produce ROS and are also important immune cells. The intracellular ROS content is very important for the overall ROS level. Therefore, the present invention selects macrophages as experimental cells for ROS level detection.
[0209] Confocal images under the same conditions ( Figure 3 ), it can be seen that the fluorescence intensity of Qu-Ka-Ca is significantly reduced compared with the control group. Therefore, the present invention proves through experiments that Qu-Ka-Ca can significantly reduce the ROS expression level of macrophages.
[0210] 2.3 Toxicity of quercetin, kaempferol, and caffeic acid in vivo and in vitro
[0211] 2.3.1 In vitro toxicity of quercetin, kaempferol, and caffeic acid
[0212] The ability and toxicity of drugs to promote proliferation are the basis for cell experiments. In the present invention, CCK-8 detection reagent is used to detect the number of cells co-cultured for 1, 4, and 7 days with PBS, CMC-Na, and Qu-Ka-Ca cells. The chemical composition of CCK-8 is 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonic acid benzene)-2H-tetrazole monosodium salt, which is reduced to a highly water-soluble yellow formazan product (Formazan) by dehydrogenase in the cell mitochondria under the action of the electron carrier 1-methoxy-5-methylphenazine dimethyl sulfate (1-Methoxy PMS), and the number of formazans generated is proportional to the number of living cells. After using CCK-8 detection reagent and cells to co-incubate for 120 minutes, the absorbance value detected in the microplate reader is proportional to the number of living cells. The control group is regarded as the untreated group, and its proliferation behavior can be regarded as natural proliferation. If the ratio of the Qu-Ka-Ca treated cells to the control group is less than 1, it can be regarded as a negative growth in the number of cells, which is a manifestation of drug toxicity. If the ratio is greater than 1, it is regarded as promoting cell proliferation. Figure 4 As shown, the cell proliferation rates on the first day were 1.01, 0.763, 1.44, 1.24, 1.31, and 1.05, respectively. Except for the 0.11-fold standard concentration group, whose proliferation rate was lower than 1, the other groups all showed a significant proliferation-promoting effect. On the fourth day, the proliferation rates of the groups were 2.99, 3.00, 3.24, 2.62, 2.93, and 3.01, respectively. Similarly, on the seventh day, the proliferation rates of the groups were 7.03, 7.25, 6.51, 5.66, 6.05, and 6.47, respectively. The group with the lowest proliferation rate was the standard concentration group, whose proliferation rate was 80.5% of the control group, which was within the acceptable range of toxicity.
[0213] 2.3.2 Toxicity of quercetin, kaempferol, and caffeic acid in vivo
[0214] Oral medication often has the characteristic of a long cycle, so the metabolism of drug molecules in the body is very important. It is known from the literature that some substances that are not toxic in themselves will become toxic substances during the enzymatic decomposition process. Therefore, only a simple in vitro toxicity proliferation experiment cannot fully describe the toxicity of drug molecules. In the present invention, the liver and kidney of mice in the animal experiment were removed, sliced and stained, and their morphology was observed under an optical microscope and compared with the normal group. Figure 5 As shown in the HE staining images of liver and kidney tissues, there was no obvious atrophy and lesions in the hepatic sinusoids and hepatocytes, and the glomeruli and tubules were normal in morphology. It can be considered that oral administration of Qu-Ka-Ca for two weeks will not cause significant effects on the liver and kidneys.
[0215] 2.4 The ability of quercetin, kaempferol and caffeic acid to promote osteogenic differentiation
[0216] The main feature in the osteogenic differentiation process is bone matrix synthesis, secretion, mineralization and maturation, and mineralized nodules are the signs of osteoblast differentiation and maturation. Therefore, in the late stage of osteogenic differentiation, characterizing calcium nodules is an important characterization method. Alizarin red is a silver ion dye that can be complexed with many metal ions to form an orange-red complex. Therefore, alizarin red can combine the calcium ions in the calcium nodules to make them appear orange-red, and the number and area of the calcium nodules also represent the degree of osteogenic differentiation. The present invention uses alizarin red staining kit to dye, and collects images under an inverted microscope, calculates the area and number of calcium nodules in the image in ImageJ software, and then imports the data into Graph Pad Prism 9 software to analyze the difference between the control group and the Qu-Ka-Ca group.
[0217] Images collected from an inverted microscope ( Figure 6 As can be seen in a), the number and area of red complexed calcium nodules in the field of view of the Qu-Ka-Ca group are larger. In the semi-quantitative analysis ( Figure 6 b), the proportion of calcium nodules in each group was 29%, 34.7%, and 58%, respectively. There were significant differences between the Qu-Ka-Ca group and the control group and the CMC-Na group, proving that Qu-Ka-Ca can significantly promote osteogenic differentiation and maturation.
[0218] Alkaline phosphatase (ALP) is mostly secreted by osteoblasts, so the ALP content is positively correlated with the number of osteoblasts. By detecting the ALP level, the relative amount of osteoblasts can be indirectly measured. It is designed that there is no significant difference in the proportion of mesenchymal stem cells differentiating into osteoblasts under the stimulation of the same osteogenic induction solution, and then Qu-Ka-Ca or PBS is added at the same time for co-culture. If the Qu-Ka-Ca group is significantly reduced compared to the control group, it is considered that Qu-Ka-Ca prevents osteoblast differentiation. If the Qu-Ka-Ca group is significantly increased compared to the control group, it is considered that Qu-Ka-Ca promotes osteogenic differentiation. Therefore, the present invention uses mesenchymal stem cells plus osteogenic induction solution for culture, and osteoblasts are detected on the 9th day of culture. ALP exists in cells, so osteoblasts need to be lysed. In order to ensure the effect of cell number on ALP production, a portion of the liquid in each group is tested by BCA, and the level of ALP is measured by ratio. The absorbance ratios were imported into Graph Pad Prism 9 for differential analysis (e.g. Figure 7The ALP contents of the three groups were 13.79mM, 11.48mM, and 16.41mM, respectively, and the ALP / BCA was 68.97U / mg, 56.01U / mg, and 77.99U / mg, respectively. Obviously, mesenchymal stem cells treated with Qu-Ka-Ca differentiated more into osteoblasts, proving that it is beneficial to osteogenic differentiation.
[0219] The hematoxylin in the HE staining solution combines with the cell nucleus to stain it blue, and eosin makes the cytoplasm appear red. Because different cell nuclei occupy different volumes in the entire cell, this also leads to certain color differences between different cells under an optical microscope. In this way, we can roughly distinguish between bone tissue and bone marrow contents, such as Figure 8 As shown, it can be seen that the bone tissue represented by light red is more abundant in the Qu-Ka-Ca group, which means that the Qu-Ka-Ca group produces more new bone in the pore-forming area.
[0220] In Masson staining, collagen fibers and cartilage are stained blue, and red blood cells are stained red. Fig. 9 As shown in the figure, compared with the control group, the Qu-Ka-Ca group has more blue areas, which means more collagen fibers. Collagen fibers are the main component of the organic components of bone tissue, proving that the Qu-Ka-Ca group can promote the generation of new bone tissue.
[0221] 2.5 Quercetin, kaempferol and caffeic acid inhibit osteoclast differentiation ability
[0222] Tartaric acid-resistant acid phosphatase is one of the hallmark substances produced by osteoclasts. Macrophages fuse into osteoclasts under the induction of RANKL inducing factor. At 5-9 days of induction, macrophages can be observed under a light microscope to aggregate with each other and fuse their cell membranes to form a huge multinucleated cell. After osteoclast formation, tartaric acid-resistant acid phosphatase is produced. Under acidic conditions containing tartaric acid, tartaric acid-resistant acid phosphatase can hydrolyze naphthol AS-BI phosphate. The produced naphthol AS-BI immediately binds to fastred or hexazo para-fuchsin to form an insoluble red dye at the enzyme active site.
[0223] After staining, images were collected under an inverted microscope. Fig.10 As shown in the figure, the control group contained an average of 10 osteoclasts under the same field of view, while the Qu-Ka-Ca group had only 3 osteoclasts under the same conditions. After ImageJ software analysis, the osteoclast areas of the control group, CMC-Na group, and Qu-Ka-Ca group were 4.899 μm 2 、3.9μm 2 、0.241μm 2, the Qu-Ka-Ca group was significantly different from the first two groups. Therefore, it can be seen that the macrophages treated with Qu-Ka-Ca rarely fuse into osteoclasts, while most of the macrophages treated with PBS fuse into osteoclasts. Therefore, the present invention believes that Qu-Ka-Ca prevents the process of macrophages fusing into osteoclasts.
[0224] At the same time, in order to gain a deeper understanding of the reasons for the differences in osteoclast differentiation, PCR technology was used to detect the differences in the expression of osteoclast-related genes in macrophages under different groups of culture. Bone is composed of minerals and organic components. After the minerals are absorbed, the absorption process of the organic components begins. The absorption of organic matter depends on tissue proteinase K (CTSK) and matrix metalloproteinase 9 (MMP-9). The differentiation of osteoclasts requires the MAPK and NF-κB pathways, in which the expression of the C-Fos / NFATC-1 gene is induced. Therefore, C-Fos / NFATC-1 is extremely important for osteoclast differentiation. The ERK branch in the MAPK pathway is responsible for cell proliferation, which plays an important role in the proliferation of osteoclasts. Fig.11 As shown in the figure, during the characterization of gene expression levels, it was found that after treatment with quercetin, kaempferol and caffeic acid, the expression of genes such as CD40L, MMP-9, C-Fos were significantly downregulated, and the expression levels of CTSK, NFATC1 and MAPKs genes were significantly different from those of the control group, which were decreased by 49.4%, 48.5% and 30% respectively compared with the control group.
[0225] 2.6 Anti-inflammatory effects of quercetin, kaempferol, and caffeic acid
[0226] NF-κB is an important inflammatory pathway. There are many NF-κB pathway activating factors, such as TNF-α, IL-1β, IL-2, etc. The present invention selects TNF-α as the activator of the NF-κB pathway. After the pathway is activated, it is evaluated whether the process is inhibited or reduced after treatment with Qu-Ka-Ca. It is known from the literature that the P65 protein exists in the cytoplasm and will be phosphorylated and enter the cell nucleus under the stimulation of the TNF-α factor, thereby stimulating the downstream inflammatory pathway. Therefore, if the phosphorylation of P65 into the nucleus is inhibited, the NF-κB pathway will be blocked. In this experiment, the NF-κB pathway detection kit of Biyuntian was used. A high-power water mirror is used in laser confocal image acquisition to observe the fluorescence of the cell nucleus.
[0227] On the confocal laser image ( Fig.12), it can be clearly seen that the fluorescence intensity in the cytoplasm of the Qu-Ka-Ca group is higher than that of the control group, which also means that more P65 is trapped outside the nucleus. Through ImageJ quantitative analysis, it can be seen that the fluorescence intensity (nucleus / cytoplasm) ratios are 1.12, 0.94, and 0.28, respectively, and the Qu-Ka-Ca group is 75.5% lower than the control group. Therefore, the present invention believes that the phosphorylation of P65 into the nucleus is inhibited after macrophages are treated with Qu-Ka-Ca, which also proves that Qu-Ka-Ca can block the NF-κB pathway to reduce the level of inflammation.
[0228] Inflammatory factors are also important indicators for measuring the level of inflammation. Local inflammation levels and overall inflammation levels reflect the inflammatory trends at different levels, and can also reflect the bone repair process from the side. Interleukins, tumor necrosis factors, etc. are factors that transmit regulatory signals between leukocytes, which are divided into pro-inflammatory factors based on interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) and anti-inflammatory factors based on interleukin 4 (IL-4), interleukin 9 (IL-9), interleukin 10 (IL-10) and transforming growth factor β (TGF-β). In the present invention, IL-1β, IL-6, TGF-β and IL-10 are selected as detection objects, and the corresponding ELISA detection kits are used for detection to measure the expression levels of inflammatory related factors in vivo and in vitro. The OD value obtained on the microplate reader is converted to the corresponding concentration according to the standard curve and processed on GraphPad Prism.
[0229] like Fig.13 As shown, the levels of pro-inflammatory factors in the in vitro samples were IL-1β (28.85pg / mL, 26.31pg / mL, 14.65pg / mL) and IL-6 (28.22pg / mL, 28.89pg / mL, 22.15pg / mL), which were decreased by 49.3% and 21.6% in the Qu-Ka-Ca group compared with the control group. The levels of anti-inflammatory factors were TGF-β (25.17pg / mL, 25.39pg / mL, 40.17pg / mL) and IL-10 (7.33pg / mL, 7.29pg / mL, 18.27pg / mL), which were increased by 59.6% and 149.2% in the Qu-Ka-Ca group compared with the control group.
[0230] The factor level detection in the in vivo samples is carried out according to the time points, e.g. Fig.14As shown, the levels of pro-inflammatory factors in the control group showed a trend of first decreasing and then increasing, while those in the Qu-Ka-Ca group continued to decrease. On the 21st day, the levels of pro-inflammatory factors were IL-1β (108.23pg / mL, 48.11pg / mL) and IL-6 (185.33pg / mL, 69.34pg / mL), which were 55.6% and 62.6% lower than those in the control group, respectively. The levels of anti-inflammatory factors in the control group showed a trend of continuous decrease, while those in the Qu-Ka-Ca group showed a trend of first decreasing and then increasing. On the 21st day, the levels of anti-inflammatory factors were TGF-β (65.73pg / mL, 127.65pg / mL) and IL-10 (5.62pg / mL, 12.05pg / mL), which were 94.2% and 114.4% higher than those in the control group, respectively.
[0231] Through in vivo and in vitro detection of inflammatory-related factors, it was basically confirmed that Qu-Ka-Ca has the ability to reduce the expression of pro-inflammatory factors and increase the expression of anti-inflammatory factors.
[0232] The embodiments of the present invention are described in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core idea. At the same time, changes or deformations made by those skilled in the art based on the ideas of the present invention, the specific implementation methods and application scope of the present invention, all belong to the scope of protection of the present invention. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. A pharmaceutical composition for bone repair, characterized in that: In parts by weight, the pharmaceutical composition comprises 0.5 to 10 parts of quercetin as shown in formula I, 10 to 200 parts of kaempferol as shown in formula II, and 1 to 200 parts of caffeic acid as shown in formula III.
2. The pharmaceutical composition according to claim 1, characterized in that In parts by weight, the pharmaceutical composition comprises 1 to 6 parts of quercetin as shown in formula I, 15 to 160 parts of kaempferol as shown in formula II, and 5 to 160 parts of caffeic acid as shown in formula III; Preferably, the pharmaceutical composition comprises, by weight, about 2.7 parts of quercetin as shown in formula I, about 158.5 parts of kaempferol as shown in formula II, and about 6 parts of caffeic acid as shown in formula III.
3. The pharmaceutical composition according to claim 1 or 2, characterized in that The bone repair is bone repair in osteomyelitis, such as chronic osteomyelitis; Preferably, the pharmaceutical composition further comprises one or more drugs, extracts and / or cells for bone repair; Preferably, the drug is selected from one or more of the following: cytokines, resveratrol and catechins; Also preferably, the cytokine is bone morphogenetic protein (BMP-2); Also preferably, the pharmaceutical composition is a traditional Chinese medicine composition; Also preferably, the cells are mesenchymal stem cells.
4. A pharmaceutical preparation comprising the pharmaceutical composition according to any one of claims 1 to 3 and one or more pharmaceutically acceptable excipients.
5. The pharmaceutical preparation according to claim 4, characterized in that The auxiliary material is selected from one or more of the following: diluent, wetting agent, binder, disintegrant, inclusion agent, flavoring agent, sustained-release agent, retention agent, lubricant, dispersant, plasticizer, opacifier and antioxidant; Preferably, the pharmaceutical preparation is a powder, tablet, pill, capsule, film, lozenge, granule, injection or oral solution.
6. A method for preparing the pharmaceutical composition according to any one of claims 1 to 3, characterized in that: The preparation method of the pharmaceutical composition comprises the following steps: (1) mixing the pharmaceutical composition according to any one of claims 1 to 3 and a pharmaceutically acceptable excipient, and heating until the pharmaceutically acceptable excipient is melted; wherein the weight ratio of the pharmaceutical composition to the pharmaceutically acceptable excipient is 1:0.1 to 100; and (2) After mixing evenly, cooling, and pulverizing the mixture to obtain the powder of the pharmaceutical preparation.
7. Use of the pharmaceutical composition according to any one of claims 1 to 3 or the pharmaceutical preparation according to claim 4 or 5 in the preparation of a medicament for bone repair.
8. The use according to claim 7, characterized in that The bone repair includes promoting osteogenesis, inhibiting osteoclast differentiation, blocking NF-κB pathway to reduce inflammatory levels, reducing the generation of reactive oxygen species (ROS), reducing the level of pro-inflammatory factors and / or increasing the level of anti-inflammatory factors.
9. The use according to claim 8, characterized in that The pro-inflammatory factors are interleukin 1β (IL-1β), interleukin 6 (IL-6) and / or tumor necrosis factor α (TNF-α).
10. The use according to claim 8, characterized in that The anti-inflammatory factors are interleukin 4 (IL-4), interleukin 9 (IL-9), interleukin 10 (IL-10) and / or transforming growth factor β (TGF-β).
